Gilead and Compugen Sign an Exclusive License Agreement to Develop COM503, a Novel Pre-Clinical Immunotherapy Program
Shots:
- As per the agreement, Compugen will have rights for the pre-clinical development and the later P-I trial of COM503 while Gilead holds the sole development and commercialization rights, thereafter
- Compugen will receive a total of $848M, incl. a $60M upfront payment, a $30M near-term milestone payment on IND clearance for COM503 anticipated in 2024 as well as $758M in future development, regulatory, and commercial milestone payments along with single- to low-double-digit tiered royalties on worldwide net sales
- Furthermore, the collaboration will leverage Compugen's predictive computational discovery capabilities for identifying new drug targets and biological pathways to develop innovative cancer immunotherapies
Ref: Gilead | Image: Gilead
Related News:- BMS Expands its Collaboration with Compugen to Evaluate the Combination of COM701 + Opdivo
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
